Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5 results about "Erysipelas" patented technology

An infection of the upper layer of the skin and superficial lymphatics caused by bacteria.

Traditional Chinese medicine composition for treating erysipelas and preparation method thereof

PendingCN121987698AAntibacterial agentsPlant ingredientsItea virginicaIndigofera kirilowii
The invention belongs to the technical field of traditional Chinese medicines, and provides a traditional Chinese medicine composition for treating erysipelas and a preparation method thereof. The traditional Chinese medicine composition comprises the following components: astragalus membranaceus, artemisia anomala, sappan wood, callicarpa macrophylla, winged euonymus twig, honeysuckle, purslane, lithospermum, sanguisorba officinalis, cacumen biotae and golden cypress. Pharmacodynamic experiments show that the traditional Chinese medicine composition obviously relieves lower limb swelling of erysipelas rats, reduces the content of NO in serum, increases the content of TNF-alpha in the serum, reduces the lesion score of lesion parts, and effectively improves related symptoms of erysipelas. The traditional Chinese medicine composition is wide in raw material source, easy to collect, simple in preparation process, high in safety, free of obvious adverse effects and free of adverse effects on the environment.
Owner:HEILONGJIANG UNIV OF CHINESE MEDICINE

An engineered bacillus subtilis strain for producing tagatose, a construction method and application thereof

PendingCN122256221ABacteriaMicroorganism based processesTagatoseErysipelothrix
The application discloses an engineered bacillus subtilis strain for producing tagatose, a construction method and application thereof, and belongs to the technical field of bioengineering. The engineered strain takes bacillus subtilis as a host, co-expresses L-arabinose isomerase from Erysipelothrix larvae and beta-galactosidase from escherichia coli, and constructs the bacillus subtilis for co-expressing double enzymes through ribosome binding sites or promoters in series. The double-enzyme bacillus subtilis whole cell catalyzes lactose to produce D-tagatose, and the yield and conversion efficiency of D-tagatose are significantly improved after optimization of the enzymatic reaction. The application adopts single-strain double-enzyme co-expression and one-step whole-cell catalysis, uses low-cost lactose as a substrate, and has the advantages of mild reaction, less by-product, simplified process, no endotoxin safety hazard, and the like. The application solves the problems of low conversion rate, high substrate cost and complicated strain compounding in the prior art, and is suitable for industrialized production of food-grade D-tagatose.
Owner:TIANJIN YEAHE BIOTECHNOLOGY CO LTD

3-hydroxypropyl esters as antimicrobial agents

PendingCN121419755ABiocideCosmetic preparationsBacterial vaginosisImpetigo contagiosa
The present invention relates generally to the use of a compound of formula (I) as defined herein as an active ingredient. Furthermore, the present invention relates to a method for inhibiting or preventing the growth of one or more microorganisms, and a method for inhibiting or reducing the conversion of sweat components to odorous compounds. The invention also relates to a compound of formula (I) as defined herein for use in the treatment of inflammation, post-inflammatory pigmentation, atopic dermatitis, bacterial vaginosis, tinea pedis, neonatal exfoliative dermatitis, contagious impetigo, furuncle and carbuncle, folliculitis, impetigo and / or erysipelas and for use as an antimicrobial agent, a mixture comprising one or two compounds of formula (I) as defined herein, and a mixture comprising one or two compounds of formula (I) as defined herein and one or more other antimicrobial agents. Finally, the present invention relates to a deodorant, a rinse-on product and a rinse-free product as defined herein.
Owner:SYMRISE GMBH & CO KG

Vaccine for swine erysipelothrix erysipelas and porcine parvovirus

The present invention relates to a vaccine comprising a non-replicating immunogen of swine erysipelothrix erysipelas and a non-replicating immunogen of porcine parvovirus, the use of a first vaccine in the prophylactic treatment of a pig against infection of erysipelothrix erysipelas and infection of porcine parvovirus by injecting the first vaccine into the corium layer of the pig.
Owner:INTERVET INT BV

Traditional Chinese medicine liniment for relieving swelling and pain and preparation method thereof

PendingCN121360205AAntibacterial agentsAntipyreticAcute cellulitisToxic material
The invention relates to a traditional Chinese medicine liniment for relieving swelling and pain and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine preparations. The traditional Chinese medicine liniment is prepared from the following components in parts by weight: 40-60 parts of rheum officinale, 45-55 parts of radix angelicae, 50-55 parts of turmeric, 40-55 parts of golden cypress, 15-25 parts of rhizoma arisaematis, 15-20 parts of pericarpium citri reticulatae, 15-30 parts of rhizoma atractylodis, 20-25 parts of mangnolia officinalis, 15-25 parts of liquorice and 80-120 parts of radices trichosanthis. The traditional Chinese medicine liniment has the effects of clearing away heat and toxic materials, dispersing blood stasis, relieving swelling and pain and the like. The traditional Chinese medicine composition is widely used for eczema, acne, psoriasis, erysipelas, paronychia, soft tissue injury, acute cellulitis, acute suppurative lymphadenitis, perianal abscess, phlebitis, external humeral epicondylitis, gonarthromeningitis, swelling after fracture, burn and the like clinically.
Owner:THE FIRST AFFILIATED HOSPITAL OF TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE